AXGN (AxoGen, Inc.) Stock Financials & Earnings

AXGNAxoGen, Inc.

Mkt Cap$2B

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Revenue (TTM)$225M

Net Income (TTM)-$16M

EPS (TTM)-$0.34

Free Cash Flow (TTM)-$3M

Gross Margin74.3%

Op. Margin-3.5%

Net Margin-7.0%

FCF Margin-1.5%

P/S Ratio (TTM)7.0x

P/E Ratio (TTM)—

YoY Rev Growth+20.2%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$37M	$30M	-$7M
Q2 23	$38M	$30M	-$7M
Q3 23	$41M	$32M	-$4M
Q4 23	$43M	$34M	-$3M
Q1 24	$41M	$33M	-$5M
Q2 24	$48M	$35M	-$428K
Q3 24	$49M	$36M	-$316K
Q4 24	$49M	$38M	$2M
Q1 25	$49M	$35M	-$2M
Q2 25	$57M	$42M	$2M
Q3 25	$60M	$46M	$2M
Q4 25	$60M	$44M	-$10M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$7M	$9M	$22M
Q2 23	$7M	$11M	$19M
Q3 23	$7M	$10M	$19M
Q4 23	$7M	$7M	$22M
Q1 24	$7M	$10M	$20M
Q2 24	$7M	$9M	$20M
Q3 24	$7M	$11M	$19M
Q4 24	$7M	$9M	$20M
Q1 25	$6M	$9M	$21M
Q2 25	$7M	$10M	$24M
Q3 25	$8M	$11M	$26M
Q4 25	$12M	$15M	$27M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$14M	$30M	$44M
Q2 23	$23M	$11M	$35M
Q3 23	$37M	$1M	$39M
Q4 23	$31M	$0	$31M
Q1 24	$16M	$2M	$18M
Q2 24	$19M	$2M	$21M
Q3 24	$19M	$6M	$25M
Q4 24	$28M	$6M	$33M
Q1 25	$18M	$4M	$22M
Q2 25	$26M	$10M	$36M
Q3 25	$24M	$12M	$36M
Q4 25	$36M	$0	$36M

Shares Outstanding

Revenue Per Employee

Revenue / Employee